CANY
NGNE icon

Caxton Associates (New York)’s Neurogene NGNE Stock Holding History

Caxton Associates (New York)’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-808
Closed -$78K – 643
2021
Q4 		$78K Buy
+808
New +$98.4K 0.01% 535
2020
Q3 		– Sell
-1,060
Closed -$352K – 450
2020
Q2 		$352K Buy
+1,060
New +$276K 0.03% 210

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Caxton Associates (New York)'s NGNE Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Neurogene (NGNE) in Q1 2022, closing a stake of 808 shares — an estimated $78K sold.

Caxton Associates (New York) first reported a position in NGNE in Q2 2020 and held it in 2 quarters. The position peaked at $352K in Q2 2020. 81 funds tracked by Wall St. Rank hold NGNE as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Neurogene position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 808 Neurogene shares in Q1 2022, an estimated $78K.
  • Caxton Associates (New York) first reported a position in Neurogene in Q2 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Neurogene position peaked at $352K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Neurogene as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.